Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for XXXX of colorectal origin.

@entity1 @entity4181 @entity901 @entity2600 @entity14 @entity298 @entity1487
BACKGROUND: We evaluate the long-term survival of @entity1 with @entity298 ( @entity298 ) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes. METHODS: One hundred sixty-seven consecutive @entity1 treated with @entity298 from @entity14 between years 1987-2006 were identified from a prospective institutional database. These @entity1 either received no chemotherapy, @entity1487 / @entity4181 or @entity901 / @entity2600 -based chemotherapy. Stratification was made according to the retrospective PSDSS that classifies @entity298 @entity1 based on clinically relevant factors. Survival analysis was performed using the Kaplan-Meier method and comparison with the log-rank test. RESULTS: Median survival was 5 months (95% CI, 3-7 months) for @entity1 who had no chemotherapy, 11 months (95% CI, 6-9 months) for @entity1 treated with 5 FU/LV, and 12 months (95% CI, 4-20 months) for @entity1 treated with @entity901 / @entity2600 -based chemotherapy. Survival differed between @entity1 treated with chemotherapy compared to those @entity1 who did not receive chemotherapy (p = 0.026). PSDSS staging was identified as an independent predictor for survival on multivariate analysis [RR 2.8 (95%CI 1.5-5.4); p < 0.001]. CONCLUSION: A trend towards improved outcomes is demonstrated from treatment of @entity1 with @entity298 from @entity14 using modern systemic chemotherapy. The PSDSS appears to be a useful tool in @entity1 selection and prognostication in @entity298 of colorectal origin.
